局限期小细胞肺癌高剂量超分割SIB放疗与标准剂量放疗的真实世界疗效比较
该回顾性研究纳入353例局限期小细胞肺癌患者,比较54 Gy超分割、45 Gy超分割和60-70 Gy常规分割同步放化疗的真实世界疗效;54 Gy组中位无进展生存和总生存均显著优于其他两组,治疗相关毒性相似。
要点
- 54 Gy超分割组中位PFS 29.7个月,优于45 Gy组15.0个月和60 Gy组13.5个月。
- 54 Gy组中位OS 63.9个月,优于45 Gy组42.9个月和60 Gy组38.0个月。
- 三组治疗相关毒性相似,54 Gy方案耐受性良好。
核心结论
- 在高剂量加速超分割每日两次胸部放疗54 Gy方案在真实世界局限期小细胞肺癌患者中耐受良好且有效。
- 与标准剂量45 Gy每日两次和60-70 Gy每日一次相比,54 Gy组无进展生存和总生存均更优。
研究设计与样本
- 单中心回顾性研究,纳入北京大学肿瘤医院病理或细胞学确诊的局限期小细胞肺癌患者353例。
- 患者按放疗剂量分为54 Gy组(30次每日两次)、45 Gy组(30次每日两次)和60 Gy组(60-70 Gy,30-35次每日一次),均接受4周期胸部放疗联合同期化疗(顺铂或卡铂联合依托泊苷)。
- 主要终点为真实世界无进展生存和总生存,采用逆概率治疗加权平衡组间特征。
主要发现
- 中位随访54.9个月(范围2.9-151.6个月)。
- 三组治疗相关毒性相似。
关键数值与推荐
- 高剂量加速超分割每日两次胸部放疗54 Gy(30次)可作为局限期小细胞肺癌的真实世界有效方案参考。
- 标准剂量对照包括45 Gy每日两次(30次)和60-70 Gy每日一次(30-35次)。
临床怎么用
- 对于局限期小细胞肺癌同步放化疗患者,可考虑采用54 Gy每日两次超分割胸部放疗以改善生存。
- 该方案治疗相关毒性与标准剂量放疗相似,耐受性良好。
局限性
- 回顾性单中心研究设计,可能存在选择偏倚。
- 研究仅纳入北京大学肿瘤医院患者,外推性需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A phase 3 trial has shown that high-dose, accelerated, hyperfractionated, twice-daily thoracic radiation therapy (54 Gy in 30 fractions) is clinically effective for patients aged <70 years with limited-stage small cell lung cancer (LS-SCLC). This retrospective study compares the real-world effectiveness of high-dose hyperfractionated simultaneous integrated boost radiation therapy with standard-dose radiation therapy. METHODS AND MATERIALS: This retrospective study was conducted at Peking University Cancer Hospital, including patients with histologically or cytologically confirmed LS-SCLC. All eligible patients received 4 courses of thoracic radiation therapy combined with concurrent chemotherapy (cisplatin or carboplatin and etoposide). Patients were categorized into 3 groups based on the radiation therapy dose: (1) the 54 Gy group (54 Gy in 30 fractions, twice daily); (2) the 45 Gy group (45 Gy in 30 fractions, twice daily); and (3) the 60 Gy group (60-70 Gy in 30-35 fractions, once daily). The primary endpoints were real-world progression-free survival and overall survival. RESULTS: Between March 2010 and November 2024, a total of 353 patients were included in the study. The median follow-up was 54.9 months (range, 2.9-151.6 months). After applying inverse probability of treatment weighting (IPTW), the clinical features were well balanced between the groups. The median real-world progression-free survival was significantly better in the 54 Gy group (29.7 months [95% CI, 15.9-not reached]) compared with the 45 Gy group (15.0 months [95% CI, 11.8-30.4]; hazard ratio [HR], 1.23 [95% CI, 1.01-1.50]) and the 60 Gy group (13.5 months [95% CI, 11.4-15.9]; HR, 1.29 [95% CI, 1.09-1.54]) both before (P = .011) and after (P = .033) IPTW. The median overall survival was also significantly longer in the 54 Gy group (63.9 months [95% CI, 57.1-not reached]) compared with the 45 Gy group (42.9 months [95% CI, 32.3-70.8]; HR, 1.76 [95% CI, 1.19-2.61]) and the 60 Gy group (38.0 months [95% CI, 30.8-51.9]; HR, 1.60 [95% CI, 1.05-2.44]) both before (P = .015) and after (P = .006) IPTW. Treatment-related toxicities were similar across the 3 groups. CONCLUSIONS: High-dose, accelerated, hyperfractionated, twice-daily thoracic radiation therapy (54 Gy) was well tolerated and effective in this large, real-world cohort study of patients with LS-SCLC compared with standard-dose (45 Gy twice daily and 60-70 Gy every day) radiation therapy.
引用
- Yu J, Zhang J, Chang X, et al. Real-World Clinical Outcomes in Patients With Limited-Stage Small Cell Lung Cancer Who Received High-Dose Hyperfractionated Simultaneous Integrated Boost Radiation Therapy Versus Standard-Dose Radiation Therapy. Pract Radiat Oncol. 2026. PMID: 42034286. doi:10.1016/j.prro.2026.04.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。